Top 10 potential targets (EP300, EGFR, TP53, RPS27A, MYC, HSP90AA1, UBC, AKT1, GAPDH, HSPA8) of active compounds from Nux vomica were predicted to be associated with MG treatment. The gene discussed is HSP90AA1; the disease is myasthenia gravis.